A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
At a glance
- Drugs BBT 877 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Bridge Biotherapeutics
- 02 Feb 2019 Status changed from planning to recruiting.
- 16 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019, according to a Bridge Biotherapeutics media release.
- 16 Jan 2019 According to a Bridge Biotherapeutics media release, this study will begin next month.